Vendor, Overland Park, KS
Altasciences Clinical Kansas Inc.
UEI WZ5RGEMMQ3W9, CAGE 6PS73
5 awards and $3,539,436 obligated between June 5, 2024 and July 23, 2026, 100% under full and open competition, against 1.0 offers on average where reported.
Sells to
Awarding agencies by dollars.
| National Institutes of Health | $3,514,436 |
| Food and Drug Administration | $25,000 |
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $3,393,307 |
| Professional, Scientific, and Technical ServicesNAICS 541712 | $146,129 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 5 |
| Delivery Order | 3 |
| Definitive Contract | 2 |
Hear when Altasciences Clinical Kansas Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
Contracts Altasciences Clinical Kansas Inc. holds whose performance ends in the next 19 months, by published end date. Each one is a recompete to prepare for.
- Ending
- 1
- Obligated so far
- $1,724,199
- Soonest
- March 10, 2027
The 1 contract, the office behind each one and the dates are in the workspace. See them
Competes with
Vendors selling research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology) to National Institutes of Health, by dollars.
| Leidos Biomedical Research Inc.Frederick, MD | $2,186,453,292 |
| Westat, Inc.Bethesda, MD | $762,955,645 |
| Technical Resources International, Inc.Bethesda, MD | $196,391,189 |
| Duke UniversityDurham, NC | $158,720,487 |
| MriglobalKansas City, MO | $117,921,746 |
| The Johns Hopkins UniversityBaltimore, MD | $100,932,043 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N95024F00001Delivery Order, September 12, 2024, Full and Open Competition | National Institutes of Health NidaNational Institutes of Health | Investigational Agent Single Ascending Dose Safety, Tolerability, and PK Study. September 3, 2024 to March 2, 2026. N01DA-23-8935NAICS 541715, PSC AN11 | $1,724,199 |
| 75N95025F00001Delivery Order, May 2, 2025, Full and Open Competition | National Institutes of Health NidaNational Institutes of Health | Investigational Agent Single Ascending Dose Safety, Tolerability, and PK Study. Pop: 5/2/2025 - 11/1/2026. N01DA-23-8935NAICS 541715, PSC AN11 | $1,644,109 |
| HHSN271201700056CDefinitive Contract, July 31, 2024, Full and Open Competition, 1 offers | National Institutes of Health NidaNational Institutes of Health | Pharmacokinetic and Pharmacodynamic Studies for Medications Development. September 20, 2017 Through September 19, 2022NAICS 541712, PSC AN11 | $146,129 |
| 75F40121C00199Definitive Contract, June 5, 2024, Full and Open Competition, 1 offers | FDA Office of Acq Grant SVCSFood and Drug Administration | Ratification of an Unauthorized Commitment for the Dose Finding Study of Kratom Alkaloids PilotNAICS 541715, PSC B537 | $25,000 |
| 75N95023F00001Delivery Order, March 13, 2025, Full and Open Competition | National Institutes of Health NidaNational Institutes of Health | Pharmacokinetic and Pharmacodynamic Trials for Medication Development in Sud. TO1 Phase 1 Cocaine Drug Interaction September 25, 2023 to JulNAICS 541715, PSC AN11 | -$0 |
- Product and service codes
- AN11 Health R&D Services; Health Care Services; Basic ResearchB537 Medical and Health Studies
- Transactions
- 11 across 5 awards